Premium
Biotin‐conjugated anti‐CD44 antibody–avidin binding system for the improvement of chondrocyte adhesion to scaffolds
Author(s) -
Lin Hong,
Zhou Jian,
Shen Longxiang,
Ruan Yuhui,
Dong Jian,
Guo Changan,
Chen Zhengrong
Publication year - 2014
Publication title -
journal of biomedical materials research part a
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 150
eISSN - 1552-4965
pISSN - 1549-3296
DOI - 10.1002/jbm.a.34770
Subject(s) - avidin , cartilage , chondrocyte , materials science , cell adhesion , biotin , tissue engineering , adhesion , scaffold , biomedical engineering , cd44 , microbiology and biotechnology , cell , biophysics , chemistry , biochemistry , medicine , biology , anatomy , composite material
The clinical need for improved treatment options for patients with cartilage injuries has motivated tissue‐engineering studies aimed at the in vitro generation of cell‐based implants with functional properties. The success of tissue‐engineered repair of cartilage may depend on the rapid and efficient adhesion of transplanted cells to the scaffold. In the present study, chondrocyte‐scaffold constructs were engineered by planting porcine chondrocytes into nonporous chitosan membranes and 3D porous chitosan scaffolds that were treated with or without biotin‐conjugated anti‐CD44 antibody–avidin binding system and avidin–biotin binding system. The spreading area, cell exfoliation rates, cell proliferation rates, histological analysis, DNA and glycosaminoglycan (GAG) content, and mRNA expression were investigated to evaluate the efficiency of biotin‐conjugated anti‐CD44 antibody–avidin binding system for the improvement of cell adhesion to scaffolds in the cartilage tissue. The results showed that the biotin‐conjugated anti‐CD44 antibody–avidin binding system improved cell adhesion to scaffolds effectively. These studies suggest that this binding system has the potential to provide improved tissue‐engineered cartilage for clinical applications. © 2013 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 102A: 1140–1148, 2014.